梁宸, 周颖, 凡畅畅, 徐鼎, 吴琪, 黄若兰, 徐尧, 罗颖. 竹节参皂苷IVa抑制三阴性乳腺癌细胞增殖的研究J. 药学学报, 2023, 58(9): 2677-2684. DOI: 10.16438/j.0513-4870.2022-1313
引用本文: 梁宸, 周颖, 凡畅畅, 徐鼎, 吴琪, 黄若兰, 徐尧, 罗颖. 竹节参皂苷IVa抑制三阴性乳腺癌细胞增殖的研究J. 药学学报, 2023, 58(9): 2677-2684. DOI: 10.16438/j.0513-4870.2022-1313
LIANG Chen, ZHOU Ying, FAN Chang-chang, XU Ding, WU Qi, HUANG Ruo-lan, XU Yao, LUO Ying. Inhibitory effect of chikusetsusaponin IVa on proliferation of triple negative breast cancer cellsJ. Acta Pharmaceutica Sinica, 2023, 58(9): 2677-2684. DOI: 10.16438/j.0513-4870.2022-1313
Citation: LIANG Chen, ZHOU Ying, FAN Chang-chang, XU Ding, WU Qi, HUANG Ruo-lan, XU Yao, LUO Ying. Inhibitory effect of chikusetsusaponin IVa on proliferation of triple negative breast cancer cellsJ. Acta Pharmaceutica Sinica, 2023, 58(9): 2677-2684. DOI: 10.16438/j.0513-4870.2022-1313

竹节参皂苷IVa抑制三阴性乳腺癌细胞增殖的研究

Inhibitory effect of chikusetsusaponin IVa on proliferation of triple negative breast cancer cells

  • 摘要: 竹节参皂苷IVa (chikusetsusaponin IVa, CsIVa) 是中药材竹节参中三萜皂苷类的天然活性单体成分, 具有抗炎症和抗肿瘤等作用, 但是其在三阴性乳腺癌(triple negative breast cancer, TNBC) 中的功能和机制尚不明确。本研究探讨了CsIVa对三阴性乳腺癌MDA-MB-231细胞增殖的抑制作用及分子机制。通过CCK8法、Edu掺入法、平板克隆法及增殖标记物检测发现CsIVa具有抑制MDA-MB-231细胞增殖的功能并且对正常乳腺细胞(MCF-10A) 无毒性作用。转录组测序分析结果显示, CsIVa抑制MDA-MB-231细胞增殖的功能与细胞周期及调控细胞周期的通路密切相关。进一步研究发现, CsIVa通过下调周期蛋白依赖性激酶1 (cyclin dependent kinase 1, CDK1)、细胞周期蛋白B1 (cyclin B1) 及上调细胞周期依赖性激酶抑制因子1A (cyclin dependent kinase inhibitor 1A, p21) 的表达将细胞周期阻滞于G2/M期。并且CsIVa对细胞周期的阻滞作用是通过抑制磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B (AKT) 信号通路的活性来实现的。综上所述, CsIVa通过抑制PI3K/AKT信号通路的活性调控细胞周期相关蛋白(p21、CDK1、cyclin B1) 的表达, 阻滞TNBC细胞周期, 从而发挥抗肿瘤的活性。

     

    Abstract: Chikusetsusaponin IVa (CsIVa) is a natural active monomer of triterpene saponins in the Chinese herbal medicine of Panax japonicus, which has anti-inflammatory, anti-tumor and other effects. However, its function and mechanism in triple negative breast cancer (TNBC) remain unclear. This study investigated the inhibitory effect and mechanisms of CsIVa on the proliferation of triple negative breast cancer cell line MDA-MB-231. In this study, we found that CsIVa could significantly inhibit the proliferation of MDA-MB-231 cells and eliminate its potential toxic effect on normal breast cells (MCF-10A). The transcriptome sequencing results showed that the inhibition of proliferation of MDA-MB-231 cells by CsIVa was closely related to cell cycle and the pathway regulating cell cycle. Further studies confirmed that CsIVa blocked the cell cycle in G2/M phase by down-regulating the expression of cyclin dependent kinase 1 (CDK1), cyclin B1 and up-regulating the expression of cyclin dependent kinase inhibitor 1A (p21). Moreover, CsIVa can block cell cycle through inhibiting PI3K/AKT signal pathway. In conclusion, CsIVa regulates the expression of cell cycle related proteins (p21, CDK1, cyclin B1) via inhibiting the activity of PI3K/AKT signaling pathway, blocks TNBC cell cycle, and thus exerts its anti-tumor activity.

     

/

返回文章
返回